Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
Like many states across the country, COVID-19 cases and deaths have impacted communities of color in
Michigan at disproportionately higher rates than whites. A staggering reality is that while African Americans
(AA) represent only 13.6% of Michigan’s population, they represent 40% of the deaths from COVID-19. Half of
the cases and deaths in Michigan occurred in Wayne County. Other Counties in the lower half of Michigan
have similar disparities including Genesee, Washtenaw, and Kent. In Genesee County, where African
Americans represent 20.3% of the population, they represent 35% of COVID-19 cases and 45% of deaths. In
Washtenaw County, nearly half of the cases to date are located in two majority low-income zip codes in the city
of Ypsilanti. African American residents, who make up 12% of the Washtenaw population, disproportionately
constitute more than a quarter of the cases. And in Kent County, while 10.8% of the population is Latinx (LX),
this ethnic group makes up 32.4% of COVID-19 cases. It is unquestionable that this crisis has exacerbated
existing racial/ethnic inequity and health disparities in Michigan. Preliminary data from the state reveal that
these disparities will likely worsen due to significant hesitancy, fear, mistrust and misinformation regarding the
COVID-19 vaccine if nothing is done to change current trends. This proposal, entitled Community-Centered
Interventions for Improved Vaccine Uptake for COVID (CIVIC), is designed to directly address and decrease
COVID-19 vaccine hesitancy and increase vaccine uptake among populations that experience COVID-19
related disparities. We will focus on the four counties within Michigan where a disproportionate burden of
COVID-19 is within AA and LX communities, i.e., Wayne, Genesee, Kent and Washtenaw Counties. Using a
community-based participatory research (CBPR) approach, CIVIC will leverage: its long term relationships
with the communities involved, an established CBPR Steering Committee developed and the knowledge
gained as a Community Engagement Alliance (CEAL) grant recipient, the resources and networks of the
University of Michigan CTSA (MICHR), and the expertise of our academic partners to identify and understand
factors that contribute to COVID-19 vaccine hesitancy in AA and LX communities in Michigan. We will develop
and test interventions based on community-centered approaches to achieve a primary goal of increased
vaccine uptake. We will achieve this goal with the following aims: 1: Increase understanding of the barriers
and drivers of vaccine uptake and hesitancy; 2: Increase vaccine uptake and decrease vaccine hesitancy
through the implementation and evaluation of a multilevel intervention; 3: Increase vaccine uptake and
decrease vaccine hesitancy through the implementation and evaluation of an individual level tailored
intervention; and 4: Maintain, enhance, and evaluate the effectiveness of the CIVIC partnership to equitably
engage all partners.
Public Health Relevance Statement
This proposal, entitled Community-Centered Interventions for Improved Vaccine Uptake for COVID (CIVIC)
involves a community-based intervention designed to increase the uptake of the COVID-19 vaccine in African-
American and Latinx communities. Using a community-based participatory research (CBPR) approach, CIVIC
will leverage our long term relationships with our expert community partners, the resources and networks of the
University of Michigan CTSA (MICHR), our CBPR partnership developed and knowledge gained as a
Community Engagement Alliance (CEAL) grant recipient, and the proficiency of our academic partners, to
identify and understand factors that contribute to COVID-19 vaccine hesitancy in AA and LX communities in
Michigan and develop and test novel multilevel interventions to achieve the primary goal of increased vaccine
uptake.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAfrican AmericanAfrican American populationCOVID-19COVID-19 burdenCOVID-19 disparityCOVID-19 misinformationCOVID-19 mortalityCOVID-19 vaccineCessation of lifeChurchCitiesColorCommunitiesCommunity Health AidesCountryCountyDataDecision MakingDisparityEquityEthnic PopulationEvaluationFaith-based organizationFrightGoalsGrantHispanicIndividualInternetInterventionInterviewKnowledgeLatinxLearningLettersLow incomeMichiganOwnershipPopulationPositioning AttributeProcessPublic HealthRaceRacial EquityRandomizedResearchResourcesSocial MarketingTestingTrainingUniversitiescommunity based participatory researchcommunity engagementcommunity interventioncommunity involvementcommunity partnerscommunity-centeredcomparison interventionculturally appropriate interventiondesigneffectiveness evaluationethnic disparityexperiencehealth disparityhealth equityhealth equity promotionhealth inequalitiesimprovedinterestknowledge integrationmembernoveloutcome disparitiesresponseshared decision makingsuccesstherapy designtrenduptakevaccine acceptancevaccine hesitancyweb site
National Institute on Minority Health and Health Disparities
CFDA Code
307
DUNS Number
073133571
UEI
GNJ7BBP73WE9
Project Start Date
26-April-2021
Project End Date
31-January-2026
Budget Start Date
01-February-2025
Budget End Date
31-January-2026
Project Funding Information for 2025
Total Funding
$614,078
Direct Costs
$396,966
Indirect Costs
$217,112
Year
Funding IC
FY Total Cost by IC
2025
National Institute on Minority Health and Health Disparities
$614,078
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01MD016867-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01MD016867-05
Patents
No Patents information available for 5R01MD016867-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01MD016867-05
Clinical Studies
No Clinical Studies information available for 5R01MD016867-05
News and More
Related News Releases
No news release information available for 5R01MD016867-05
History
No Historical information available for 5R01MD016867-05
Similar Projects
No Similar Projects information available for 5R01MD016867-05